TapImmune Inc.
2815 Eastlake Avenue East
Suite 300
Seattle
Washington
98102
United States
Tel: 866-359-7541
Website: http://www.tapimmune.com/
Email: ir@TapImmune.com
161 articles about TapImmune Inc.
-
TapImmune Provides Second Quarter 2017 Corporate And Clinical Update
9/1/2017
-
TapImmune To Provide Second Quarter 2017 Business Update Conference Call And Webcast
8/29/2017
-
TapImmune Amends Phase II Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments
8/8/2017
-
TapImmune Reaches 50% Patient Enrollment Benchmark In Phase II Study Of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer
6/27/2017
-
TapImmune Enters Into Definitive Agreements To Raise $6.82 Million In A Private Placement From Accredited Investors And From The Exercise Of Warrants By Existing Institutional Investors
6/22/2017
-
TapImmune Provides First Quarter 2017 Corporate And Clinical Update
6/1/2017
-
TapImmune To Provide First Quarter 2017 Business Update Conference Call And Webcast
5/18/2017
-
TapImmune COO Resigns To Pursue New Opportunities, Effective Immediately
5/1/2017
-
Richard Kenney, MD, FACP, Joins TapImmune To Lead The Clinical Development Program
5/1/2017
-
TapImmune Provides Year End 2016 Corporate and Clinical Update
3/15/2017
-
TapImmune Announces Fully Funded Phase II Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer
3/14/2017
-
TapImmune Advances TPIV 200 Phase II Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review
2/15/2017
-
TapImmune Expands Intellectual Property On PolyStart Platform For Use In Next-Generation T-Cell Vaccines
2/7/2017
-
TapImmune Completes Scale-Up And GMP Manufacturing Of TPIV 200 Vaccine To Supply Additional Phase 2 Clinical Trials
2/2/2017
-
TapImmune Release: Pharma Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial
1/24/2017
-
TapImmune Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients
1/10/2017
-
TapImmune: Year End 2016 Update
1/3/2017
-
TapImmune Commences Trading On The Nasdaq Capital Market
11/9/2016
-
TapImmune Approved For Listing On The Nasdaq Capital Market
11/3/2016
-
TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine
11/1/2016